Azienda USL IRCCS Di Reggio Emilia

At Azienda USL IRCCS Di Reggio Emilia, the Hematology Unit is actively involved in studies across hemic and lymphatic diseases and neoplasms, with a strong focus on follicular lymphoma, marginal zone lymphoma, and multiple myeloma. These trials are mainly designed to compare new treatment combinations, refine disease control, and improve outcomes for patients with relapsed, refractory, or newly diagnosed blood cancers.

• Testing targeted and antibody-based treatments for follicular lymphoma and marginal zone lymphoma
• Evaluating new approaches for relapsed/refractory multiple myeloma and newly diagnosed multiple myeloma
• Assessing whether newer therapies can improve response rates and disease control

This research reflects a broad effort to advance more effective and better-tolerated options for complex hematologic cancers.

The site also contributes to oncology research in several solid tumors, including breast cancer, ovarian cancer, cholangiocarcinoma, pancreatic cancer, gastroesophageal adenocarcinoma, renal cell carcinoma, and glioblastoma. These studies are aimed at testing new therapies, confirming treatment benefit in real-world settings, and improving survival or delaying disease progression.

• Studying new treatment options for advanced ovarian cancer and other difficult-to-treat tumors
• Evaluating therapies for metastatic breast cancer and renal cell carcinoma
• Exploring novel approaches for aggressive cancers such as glioblastoma and pancreatic cancer

This work highlights the center’s role in advancing cancer care through trials focused on both newly diagnosed and advanced disease.

Clinical research at the site extends beyond cancer into respiratory tract diseases, nutritional and metabolic diseases, and musculoskeletal diseases. Current studies include chronic obstructive pulmonary disease, gout with hyperuricemia, and thrombotic disease, with the goal of improving symptom control, reducing complications, and testing more effective treatment strategies.

• Assessing new options for COPD in patients with frequent exacerbations
• Comparing treatments for gout to better control uric acid levels
• Investigating therapies for proximal deep vein thrombosis to support clot resolution and safety

These studies show a diverse research portfolio that includes chronic inflammatory and vascular conditions alongside oncology.

Several trials at Azienda USL IRCCS Di Reggio Emilia are focused on more personalized care, using disease markers and molecular features to guide treatment decisions in colon cancer, breast cancer, and multiple myeloma. The aim is to improve how patients are selected for therapy, strengthen monitoring tools, and evaluate whether targeted treatment strategies can lead to better outcomes.

• Using biomarkers to guide treatment decisions in early breast cancer and colon cancer
• Improving disease monitoring in multiple myeloma
• Supporting more precise and individualized cancer care

This area of research emphasizes the growing role of biomarker-driven trials in modern clinical practice.